SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. has announced the extensive growth of hair from the spinal cord of mice that were transplanted with hair follicles which contain pluripotent stem cells, in order to repair spinal injury. AntiCancer Inc. has previously discovered that hair follicles pluripotent contain stem cells that can differentiate into nerve and other types of cells, that can be used for regenerative medicine. AntiCancer Inc. has reported the extensive hair growth in the spinal cord in the latest issue of PLOS ONE (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133475).
“It was a surprise to see long hairs growing from the spinal cord of mice that were repaired with hair follicle stem cells for spinal cord injury,” said Charlene Cooper, Vice President and Chief Operating Officer of AntiCancer Inc. “This phenomenon indicates that there may be factors in the spine that strongly promote hair growth that could be useful for promoting hair growth from the scalp for people with hair loss. The pluripotent stem cells from the hair follicle have many important advantages over other types of stem cells such as ES and iPS in that they are highly accessible, they do not produce tumors and do not have ethical issues,” said Ms. Cooper.
AntiCancer Inc., founded in 1984 and based in San Diego, with offices and laboratories in Seoul, Beijing, Nanjing and Tokyo, has developed the leading mouse models of cancer including MetaMouse®, AngioMouse® and StromaMouse®. These mouse models are made imageable with AntiCancer’s OncoBrite® technology are the models of choice for novel drug discovery for cancer. With its proprietary mouse models, AntiCancer is the foremost pre-clinical cancer contract research organization. AntiCancer offers the world’s largest collection of fluorescent-protein-expressing cancer cell lines and transgenic fluorescent nude mice. AntiCancer is a pioneer in fluorescence-guided surgery of cancer using its patient-like mouse models. AntiCancer is also developing biological drugs that target cancer-specific metabolic defects, including recombinant methioninase (rMETase). AntiCancer developed the Histoculture Drug Response Assay (HDRA) and patient-derived orthotopic xenografts (PDOX™) for individualized cancer treatment. AntiCancer is also developing tumor-targeting bacteria for the general cure of cancer. The company markets recombinant-enzyme-based diagnostics for cancer and cardiovascular disease in its wholly-owned A/C Diagnostics LLC subsidiary.
